ADC Therapeutics (ADCT) Cash from Operations (2020 - 2026)

ADC Therapeutics (ADCT) has reported Cash from Operations for 7 consecutive years, with 29710000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Operations rose 47.26% year-over-year to 29710000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 114550000.0 (up 15.82% YoY) and the FY2025 annual result came in at 141174000.0, down 14.0% from the prior year.
• Cash from Operations advanced to 29710000.0 in Q1 2026 per ADCT's latest filing, from 31123000.0 in the prior quarter.
• Over the last five years, Cash from Operations for ADCT reached as high as 2195000.0 in Q3 2022 and fell as low as 56334000.0 in Q1 2025.
• A 5-year average of 32453882.35 and a median of 31633000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 103.75% — and 2023, when it slumped 1770.75%.
• Year by year, Cash from Operations stood at 53614000.0 in 2022, then surged by 41.0% to 31633000.0 in 2023, then soared by 30.92% to 21852000.0 in 2024, then slumped by 42.43% to 31123000.0 in 2025, then grew by 4.54% to 29710000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 29710000.0, 31123000.0, and 29630000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.